359 related articles for article (PubMed ID: 37108214)
21. Using
Zhang Y; Cai Y; Sun S; Han T; Chen L; Hou W
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361580
[TBL] [Abstract][Full Text] [Related]
22. Cas9, Cpf1 and C2c1/2/3-What's next?
Nakade S; Yamamoto T; Sakuma T
Bioengineered; 2017 May; 8(3):265-273. PubMed ID: 28140746
[TBL] [Abstract][Full Text] [Related]
23. Deleting specific residues from the HNH linkers creates a CRISPR-SpCas9 variant with high fidelity and efficiency.
Wang G; Wang C; Chu T; Wu X; Anderson CM; Huang D; Li J
J Biotechnol; 2023 May; 368():42-52. PubMed ID: 37116617
[TBL] [Abstract][Full Text] [Related]
24. High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells.
Kim HK; Lee S; Kim Y; Park J; Min S; Choi JW; Huang TP; Yoon S; Liu DR; Kim HH
Nat Biomed Eng; 2020 Jan; 4(1):111-124. PubMed ID: 31937939
[TBL] [Abstract][Full Text] [Related]
25. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
26. Tumor microenvironment based stimuli-responsive CRISPR/Cas delivery systems: A viable platform for interventional approaches.
Tang N; Ning Q; Wang Z; Tao Y; Zhao X; Tang S
Colloids Surf B Biointerfaces; 2022 Feb; 210():112257. PubMed ID: 34894597
[TBL] [Abstract][Full Text] [Related]
27. Systematic in vitro specificity profiling reveals nicking defects in natural and engineered CRISPR-Cas9 variants.
Murugan K; Suresh SK; Seetharam AS; Severin AJ; Sashital DG
Nucleic Acids Res; 2021 Apr; 49(7):4037-4053. PubMed ID: 33744974
[TBL] [Abstract][Full Text] [Related]
28. All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo.
Ibraheim R; Song CQ; Mir A; Amrani N; Xue W; Sontheimer EJ
Genome Biol; 2018 Sep; 19(1):137. PubMed ID: 30231914
[TBL] [Abstract][Full Text] [Related]
29. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
30. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
[TBL] [Abstract][Full Text] [Related]
31. Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
Li S; Du M; Deng J; Deng G; Li J; Song Z; Han H
Acta Biomater; 2022 Dec; 154():597-607. PubMed ID: 36243370
[TBL] [Abstract][Full Text] [Related]
32. Cas9-NG Greatly Expands the Targeting Scope of the Genome-Editing Toolkit by Recognizing NG and Other Atypical PAMs in Rice.
Ren B; Liu L; Li S; Kuang Y; Wang J; Zhang D; Zhou X; Lin H; Zhou H
Mol Plant; 2019 Jul; 12(7):1015-1026. PubMed ID: 30928635
[TBL] [Abstract][Full Text] [Related]
33. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in stimuli-responsive polymeric carriers for controllable CRISPR/Cas9 gene editing system delivery.
Ma P; Wang Q; Luo X; Mao L; Wang Z; Ye E; Loh XJ; Li Z; Wu YL
Biomater Sci; 2023 Jul; 11(15):5078-5094. PubMed ID: 37282836
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in CRISPR/Cas9 mediated genome editing in Bacillus subtilis.
Hong KQ; Liu DY; Chen T; Wang ZW
World J Microbiol Biotechnol; 2018 Sep; 34(10):153. PubMed ID: 30269229
[TBL] [Abstract][Full Text] [Related]
36. [Cas9 protein variant VQR recognizes NGAC protospacer adjacent motif in rice].
Xin GW; Hu XX; Wang KJ; Wang XC
Yi Chuan; 2018 Dec; 40(12):1112-1119. PubMed ID: 30559100
[TBL] [Abstract][Full Text] [Related]
37. CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool.
Shojaei Baghini S; Gardanova ZR; Abadi SAH; Zaman BA; İlhan A; Shomali N; Adili A; Moghaddar R; Yaseri AF
Cell Mol Biol Lett; 2022 May; 27(1):35. PubMed ID: 35508982
[TBL] [Abstract][Full Text] [Related]
38. Cas9HF1 enhanced specificity in Ustilago maydis.
Zuo W; Depotter JR; Doehlemann G
Fungal Biol; 2020; 124(3-4):228-234. PubMed ID: 32220383
[TBL] [Abstract][Full Text] [Related]
39. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
[TBL] [Abstract][Full Text] [Related]
40. Expanding the range of CRISPR/Cas9-directed genome editing in soybean.
He R; Zhang P; Yan Y; Yu C; Jiang L; Zhu Y; Wang D
aBIOTECH; 2022 Jun; 3(2):89-98. PubMed ID: 36312444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
